These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16982190)

  • 1. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
    Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.
    Franciskovich JB; Masters JJ; Weber WW; Klimkowski VJ; Chouinard M; Sipes PR; Johnson LM; Snyder DW; Chastain MK; Craft TJ; Towner RD; Gifford-Moore DS; Froelich LL; Smallwood JK; Foster RS; Smith GF; Liebeschuetz JW; Murray CW; Young SC
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6910-3. PubMed ID: 17976987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.
    Kleanthous S; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chan C; Clarte MO; Convery MA; Harling JD; Hortense E; Irving WR; Irvine S; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Roethka TJ; Senger S; Shah GP; Stelman GJ; Toomey JR; Watson NS; West RI; Whittaker C; Zhou P; Young RJ
    Bioorg Med Chem Lett; 2010 Jan; 20(2):618-22. PubMed ID: 20006499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
    Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors.
    Watson NS; Brown D; Campbell M; Chan C; Chaudry L; Convery MA; Fenwick R; Hamblin JN; Haslam C; Kelly HA; King NP; Kurtis CL; Leach AR; Manchee GR; Mason AM; Mitchell C; Patel C; Patel VK; Senger S; Shah GP; Weston HE; Whitworth C; Young RJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3784-8. PubMed ID: 16697194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs.
    Jia ZJ; Wu Y; Huang W; Zhang P; Clizbe LA; Goldman EA; Sinha U; Arfsten AE; Edwards ST; Alphonso M; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1221-7. PubMed ID: 14980670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of acylguanidine FXa inhibitors.
    O'Connor SP; Atwal K; Li C; Liu EC; Seiler SM; Shi M; Shi Y; Stein PD; Wang Y
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4696-9. PubMed ID: 18644722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.
    Jia ZJ; Wu Y; Huang W; Zhang P; Song Y; Woolfrey J; Sinha U; Arfsten AE; Edwards ST; Hutchaleelaha A; Hollennbach SJ; Lambing JL; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1229-34. PubMed ID: 14980671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit.
    Zbinden KG; Anselm L; Banner DW; Benz J; Blasco F; Décoret G; Himber J; Kuhn B; Panday N; Ricklin F; Risch P; Schlatter D; Stahl M; Thomi S; Unger R; Haap W
    Eur J Med Chem; 2009 Jul; 44(7):2787-95. PubMed ID: 19200624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
    Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
    J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.
    Imaeda Y; Miyawaki T; Sakamoto H; Itoh F; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
    Bioorg Med Chem; 2008 Mar; 16(5):2243-60. PubMed ID: 18077174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthranilamide inhibitors of factor Xa.
    Mendel D; Marquart AL; Joseph S; Waid P; Yee YK; Tebbe AL; Ratz AM; Herron DK; Goodson T; Masters JJ; Franciskovich JB; Tinsley JM; Wiley MR; Weir LC; Kyle JA; Klimkowski VJ; Smith GF; Towner RD; Froelich LL; Buben J; Craft TJ
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4832-6. PubMed ID: 17624775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification.
    Komoriya S; Kobayashi S; Osanai K; Yoshino T; Nagata T; Haginoya N; Nakamoto Y; Mochizuki A; Nagahara T; Suzuki M; Shimada T; Watanabe K; Isobe Y; Furugoori T
    Bioorg Med Chem; 2006 Mar; 14(5):1309-30. PubMed ID: 16263291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs.
    Young RJ; Adams C; Blows M; Brown D; Burns-Kurtis CL; Chan C; Chaudry L; Convery MA; Davies DE; Exall AM; Foster G; Harling JD; Hortense E; Irvine S; Irving WR; Jackson S; Kleanthous S; Pateman AJ; Patikis AN; Roethka TJ; Senger S; Stelman GJ; Toomey JR; West RI; Whittaker C; Zhou P; Watson NS
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1582-7. PubMed ID: 21349710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.
    Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V
    J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties.
    Yoshikawa K; Kobayashi S; Nakamoto Y; Haginoya N; Komoriya S; Yoshino T; Nagata T; Mochizuki A; Watanabe K; Suzuki M; Kanno H; Ohta T
    Bioorg Med Chem; 2009 Dec; 17(24):8221-33. PubMed ID: 19900814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
    Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereoselective synthesis and biological evaluation of 3,4-diaminocyclohexanecarboxylic acid derivatives as factor Xa inhibitors.
    Nagata T; Nagamochi M; Kobayashi S; Komoriya S; Yoshino T; Kanno H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4587-92. PubMed ID: 18675545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
    Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.